Whether this glycolytic switch represents an attempt of the cells to resist to TMZ by impairing prodrug activation deserves in vivo evaluation, for example by testing the combined effect of MGMT inhibition and proton transporter inhibitors on the response of orthotopic glioblastomas to TMZ. This evidence concerns the gene MGMT and glioblastoma.